Petros Pharmaceuticals, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Petros Pharmaceuticals, Inc. (PTPI) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$1.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- Petros Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$784.27K, a 111.13% decline year-over-year.
- Petros Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $7.05M.
- Petros Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$2.26M.
- Petros Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $1.43M.
- Petros Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$9.63M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.65M 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | -$784.27K 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $1.43M 10-K · filed 2026-04-15 | |||
| 2025-09-30 | $2.36M 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $3.61M 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | $7.05M 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | -$9.63M 10-K · filed 2026-04-15 | |||
| 2024-09-30 | -$9.44M 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | -$5.88M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$2.26M 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |